Media stories about Amphastar Pharmaceuticals (NASDAQ:AMPH) have trended somewhat negative on Friday, according to Accern Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Amphastar Pharmaceuticals earned a news impact score of -0.01 on Accern’s scale. Accern also assigned news articles about the company an impact score of 43.488017974183 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the media stories that may have impacted Accern Sentiment’s scoring:
Several brokerages have recently weighed in on AMPH. Zacks Investment Research cut Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. Piper Jaffray Companies set a $19.00 price target on Amphastar Pharmaceuticals and gave the company a “buy” rating in a research report on Sunday, October 22nd. Wells Fargo & Company reissued a “buy” rating on shares of Amphastar Pharmaceuticals in a report on Saturday, July 22nd. BMO Capital Markets reissued a “hold” rating and set a $16.00 price objective on shares of Amphastar Pharmaceuticals in a report on Monday, July 31st. Finally, Needham & Company LLC boosted their price objective on Amphastar Pharmaceuticals from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, September 27th. Two analysts have rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $20.29.
Shares of Amphastar Pharmaceuticals (AMPH) traded down 0.43% during mid-day trading on Friday, reaching $18.33. The company’s stock had a trading volume of 19,681 shares. The stock has a market capitalization of $846.75 million, a P/E ratio of 238.05 and a beta of 1.69. The company’s 50-day moving average price is $17.43 and its 200-day moving average price is $16.54. Amphastar Pharmaceuticals has a 12-month low of $12.05 and a 12-month high of $21.75.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings results on Wednesday, August 9th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.06 by $0.05. The business had revenue of $65.20 million during the quarter, compared to analyst estimates of $63.40 million. Amphastar Pharmaceuticals had a return on equity of 2.42% and a net margin of 1.61%. The company’s quarterly revenue was down 4.1% on a year-over-year basis. During the same period last year, the business posted $0.23 earnings per share. On average, equities research analysts forecast that Amphastar Pharmaceuticals will post $0.27 earnings per share for the current fiscal year.
Amphastar Pharmaceuticals declared that its board has initiated a share buyback plan on Wednesday, August 9th that authorizes the company to repurchase $20.00 million in shares. This repurchase authorization authorizes the company to repurchase up to 2.8% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s management believes its stock is undervalued.
In other Amphastar Pharmaceuticals news, Director Stephen B. Shohet sold 7,862 shares of the firm’s stock in a transaction on Thursday, October 26th. The stock was sold at an average price of $18.39, for a total value of $144,582.18. Following the sale, the director now directly owns 31,978 shares in the company, valued at $588,075.42. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Diane G. Gerst sold 8,444 shares of the firm’s stock in a transaction on Thursday, October 5th. The shares were sold at an average price of $18.87, for a total value of $159,338.28. The disclosure for this sale can be found here. Over the last quarter, insiders sold 154,038 shares of company stock valued at $2,780,352. 11.10% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION WARNING: “Somewhat Critical News Coverage Somewhat Unlikely to Affect Amphastar Pharmaceuticals (NASDAQ:AMPH) Share Price” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2017/10/27/amphastar-pharmaceuticals-amph-earns-coverage-optimism-rating-of-0-01.html.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.